APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiogenesis Therapeutic Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Angiogenesis Therapeutic Agent Market Outlook and Growth Opportunities 2026

22 December 2025209 pages

Choose your research edition.

Industry ResearchAngiogenesis Therapeutic Agent Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiogenesis Therapeutic Agent Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Angiogenesis Therapeutic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiogenesis Therapeutic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiogenesis Therapeutic Agent Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Angiogenesis Therapeutic Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Angiogenesis Therapeutic Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Angiogenesis Therapeutic Agent market include Sun Pharma, Shanghai Pharmaceuticals, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG and The Geuder Group, MORCHER GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiogenesis Therapeutic Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiogenesis Therapeutic Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiogenesis Therapeutic Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiogenesis Therapeutic Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiogenesis Therapeutic Agent Segment by Company

Sun Pharma

Shanghai Pharmaceuticals

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implandata ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Angiogenesis Therapeutic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Angiogenesis Therapeutic Agent Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Angiogenesis Therapeutic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Angiogenesis Therapeutic Agent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Angiogenesis Therapeutic Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Angiogenesis Therapeutic Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Angiogenesis Therapeutic Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Therapeutic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Therapeutic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Therapeutic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiogenesis Therapeutic Agent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Angiogenesis Therapeutic Agent industry.

Chapter 3: Detailed analysis of Angiogenesis Therapeutic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Angiogenesis Therapeutic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Angiogenesis Therapeutic Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Angiogenesis Therapeutic Agent Industry Trends Table 2. Angiogenesis Therapeutic Agent Industry Drivers Table 3. Angiogenesis Therapeutic Agent Industry Opportunities and Challenges Table 4. Angiogenesis Therapeutic Agent Industry Restraints Table 5. Global Angiogenesis Therapeutic Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Angiogenesis Therapeutic Agent Revenue Share by Company (2021-2026) Table 7. Global Angiogenesis Therapeutic Agent Sales Volume by Company (k units) & (2021-2026) Table 8. Global Angiogenesis Therapeutic Agent Sales Volume Share by Company (2021-2026) Table 9. Global Angiogenesis Therapeutic Agent Average Price (US$/unit) of Company (2021-2026) Table 10. Global Angiogenesis Therapeutic Agent Company Ranking, (2024-2026) & (USD Million) Table 11. Global Angiogenesis Therapeutic Agent Key Company Manufacturing Base & Headquarters Table 12. Global Angiogenesis Therapeutic Agent Company, Product Type & Application Table 13. Global Angiogenesis Therapeutic Agent Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiogenesis Therapeutic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diabetic Retinopathy Table 18. Significant Companies of Myopic Choroidal Neovascularization Table 19. Significant Companies of Macular Edema Table 20. Significant Companies of Macular Degeneration Table 21. Global Angiogenesis Therapeutic Agent Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Angiogenesis Therapeutic Agent Sales Volume by Type (2021-2026) & (k units) Table 23. Global Angiogenesis Therapeutic Agent Sales Volume by Type (2027-2032) & (k units) Table 24. Global Angiogenesis Therapeutic Agent Sales Volume Share by Type (2021-2026) Table 25. Global Angiogenesis Therapeutic Agent Sales Volume Share by Type (2027-2032) Table 26. Global Angiogenesis Therapeutic Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Angiogenesis Therapeutic Agent Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Angiogenesis Therapeutic Agent Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Angiogenesis Therapeutic Agent Sales Value Share by Type (2021-2026) Table 30. Global Angiogenesis Therapeutic Agent Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Online Pharmacies Table 32. Significant Companies of Hospital Pharmacies Table 33. Significant Companies of Retail Pharmacies Table 34. Global Angiogenesis Therapeutic Agent Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Angiogenesis Therapeutic Agent Sales Volume by Application (2021-2026) & (k units) Table 36. Global Angiogenesis Therapeutic Agent Sales Volume by Application (2027-2032) & (k units) Table 37. Global Angiogenesis Therapeutic Agent Sales Volume Share by Application (2021-2026) Table 38. Global Angiogenesis Therapeutic Agent Sales Volume Share by Application (2027-2032) Table 39. Global Angiogenesis Therapeutic Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Angiogenesis Therapeutic Agent Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Angiogenesis Therapeutic Agent Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Angiogenesis Therapeutic Agent Sales Value Share by Application (2021-2026) Table 43. Global Angiogenesis Therapeutic Agent Sales Value Share by Application (2027-2032) Table 44. Global Angiogenesis Therapeutic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Angiogenesis Therapeutic Agent Sales by Region (2021-2026) & (k units) Table 46. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2021-2026) Table 47. Global Angiogenesis Therapeutic Agent Sales by Region (2027-2032) & (k units) Table 48. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2027-2032) Table 49. Global Angiogenesis Therapeutic Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Angiogenesis Therapeutic Agent Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Angiogenesis Therapeutic Agent Sales Value Share by Region (2021-2026) Table 52. Global Angiogenesis Therapeutic Agent Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Angiogenesis Therapeutic Agent Sales Value Share by Region (2027-2032) Table 54. Global Angiogenesis Therapeutic Agent Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Angiogenesis Therapeutic Agent Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Angiogenesis Therapeutic Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 59. Global Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2026) Table 60. Global Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units) Table 61. Global Angiogenesis Therapeutic Agent Sales Market Share by Country (2027-2032) Table 62. Global Angiogenesis Therapeutic Agent Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Angiogenesis Therapeutic Agent Sales Value Market Share by Country (2021-2026) Table 64. Global Angiogenesis Therapeutic Agent Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Angiogenesis Therapeutic Agent Sales Value Market Share by Country (2027-2032) Table 66. Sun Pharma Company Information Table 67. Sun Pharma Business Overview Table 68. Sun Pharma Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio Table 70. Sun Pharma Recent Development Table 71. Shanghai Pharmaceuticals Company Information Table 72. Shanghai Pharmaceuticals Business Overview Table 73. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio Table 75. Shanghai Pharmaceuticals Recent Development Table 76. Johnson & Johnson Company Information Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio Table 80. Johnson & Johnson Recent Development Table 81. Novartis AG Company Information Table 82. Novartis AG Business Overview Table 83. Novartis AG Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Novartis AG Angiogenesis Therapeutic Agent Product Portfolio Table 85. Novartis AG Recent Development Table 86. Gilead Sciences, Inc. Company Information Table 87. Gilead Sciences, Inc. Business Overview Table 88. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 90. Gilead Sciences, Inc. Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Pfizer Angiogenesis Therapeutic Agent Product Portfolio Table 95. Pfizer Recent Development Table 96. Daiichi Sankyo Company Information Table 97. Daiichi Sankyo Business Overview Table 98. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio Table 100. Daiichi Sankyo Recent Development Table 101. Bayer AG Company Information Table 102. Bayer AG Business Overview Table 103. Bayer AG Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Bayer AG Angiogenesis Therapeutic Agent Product Portfolio Table 105. Bayer AG Recent Development Table 106. The Geuder Group, MORCHER GmbH Company Information Table 107. The Geuder Group, MORCHER GmbH Business Overview Table 108. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio Table 110. The Geuder Group, MORCHER GmbH Recent Development Table 111. Santen Pharmaceutical Co., Ltd. Company Information Table 112. Santen Pharmaceutical Co., Ltd. Business Overview Table 113. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio Table 115. Santen Pharmaceutical Co., Ltd. Recent Development Table 116. Regeneron Pharmaceuticals, Inc. Company Information Table 117. Regeneron Pharmaceuticals, Inc. Business Overview Table 118. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 120. Regeneron Pharmaceuticals, Inc. Recent Development Table 121. Otsuka Pharmaceutical Co. Ltd Company Information Table 122. Otsuka Pharmaceutical Co. Ltd Business Overview Table 123. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio Table 125. Otsuka Pharmaceutical Co. Ltd Recent Development Table 126. Novamedika Company Information Table 127. Novamedika Business Overview Table 128. Novamedika Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Novamedika Angiogenesis Therapeutic Agent Product Portfolio Table 130. Novamedika Recent Development Table 131. Medicom Health care Company Information Table 132. Medicom Health care Business Overview Table 133. Medicom Health care Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio Table 135. Medicom Health care Recent Development Table 136. Implandata ophthalmic products GmbH Company Information Table 137. Implandata ophthalmic products GmbH Business Overview Table 138. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio Table 140. Implandata ophthalmic products GmbH Recent Development Table 141. Genentech, Inc. Company Information Table 142. Genentech, Inc. Business Overview Table 143. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 145. Genentech, Inc. Recent Development Table 146. Eyetech Inc. Company Information Table 147. Eyetech Inc. Business Overview Table 148. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 150. Eyetech Inc. Recent Development Table 151. ERC Labs Company Information Table 152. ERC Labs Business Overview Table 153. ERC Labs Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. ERC Labs Angiogenesis Therapeutic Agent Product Portfolio Table 155. ERC Labs Recent Development Table 156. Becton, Dickinson and Company Company Information Table 157. Becton, Dickinson and Company Business Overview Table 158. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio Table 160. Becton, Dickinson and Company Recent Development Table 161. Allergan plc Company Information Table 162. Allergan plc Business Overview Table 163. Allergan plc Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. Allergan plc Angiogenesis Therapeutic Agent Product Portfolio Table 165. Allergan plc Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Angiogenesis Therapeutic Agent Distributors List Table 169. Angiogenesis Therapeutic Agent Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Angiogenesis Therapeutic Agent Product Image Figure 2. Global Angiogenesis Therapeutic Agent Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiogenesis Therapeutic Agent Sales Value (2021-2032) & (US$ Million) Figure 4. Global Angiogenesis Therapeutic Agent Sales (2021-2032) & (k units) Figure 5. Global Angiogenesis Therapeutic Agent Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Angiogenesis Therapeutic Agent Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diabetic Retinopathy Image Figure 10. Myopic Choroidal Neovascularization Image Figure 11. Macular Edema Image Figure 12. Macular Degeneration Image Figure 13. Global Angiogenesis Therapeutic Agent Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Angiogenesis Therapeutic Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Angiogenesis Therapeutic Agent Sales Volume Share by Type (2021-2032) Figure 16. Global Angiogenesis Therapeutic Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Angiogenesis Therapeutic Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Angiogenesis Therapeutic Agent Sales Value Share by Type (2021-2032) Figure 19. Online Pharmacies Image Figure 20. Hospital Pharmacies Image Figure 21. Retail Pharmacies Image Figure 22. Global Angiogenesis Therapeutic Agent Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Angiogenesis Therapeutic Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Angiogenesis Therapeutic Agent Sales Volume Share by Application (2021-2032) Figure 25. Global Angiogenesis Therapeutic Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Angiogenesis Therapeutic Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Angiogenesis Therapeutic Agent Sales Value Share by Application (2021-2032) Figure 28. Global Angiogenesis Therapeutic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Angiogenesis Therapeutic Agent Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Angiogenesis Therapeutic Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Angiogenesis Therapeutic Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Angiogenesis Therapeutic Agent Sales Value (2021-2032) & (US$ Million) Figure 33. North America Angiogenesis Therapeutic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Angiogenesis Therapeutic Agent Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Angiogenesis Therapeutic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Angiogenesis Therapeutic Agent Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Angiogenesis Therapeutic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Angiogenesis Therapeutic Agent Sales Value (2021-2032) & (US$ Million) Figure 39. South America Angiogenesis Therapeutic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Angiogenesis Therapeutic Agent Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Angiogenesis Therapeutic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Angiogenesis Therapeutic Agent Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Angiogenesis Therapeutic Agent Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Shanghai Pharmaceuticals
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implandata ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Angiogenesis Therapeutic Agent Sales Value (2021-2032)
  4. 1.2.2 Global Angiogenesis Therapeutic Agent Sales Volume (2021-2032)
  5. 1.2.3 Global Angiogenesis Therapeutic Agent Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Angiogenesis Therapeutic Agent Market Dynamics
  1. 2.1 Angiogenesis Therapeutic Agent Industry Trends
  2. 2.2 Angiogenesis Therapeutic Agent Industry Drivers
  3. 2.3 Angiogenesis Therapeutic Agent Industry Opportunities and Challenges
  4. 2.4 Angiogenesis Therapeutic Agent Industry Restraints
3 Angiogenesis Therapeutic Agent Market by Company
  1. 3.1 Global Angiogenesis Therapeutic Agent Company Revenue Ranking in 2025
  2. 3.2 Global Angiogenesis Therapeutic Agent Revenue by Company (2021-2026)
  3. 3.3 Global Angiogenesis Therapeutic Agent Sales Volume by Company (2021-2026)
  4. 3.4 Global Angiogenesis Therapeutic Agent Average Price by Company (2021-2026)
  5. 3.5 Global Angiogenesis Therapeutic Agent Company Ranking (2024-2026)
  6. 3.6 Global Angiogenesis Therapeutic Agent Company Manufacturing Base and Headquarters
  7. 3.7 Global Angiogenesis Therapeutic Agent Company Product Type and Application
  8. 3.8 Global Angiogenesis Therapeutic Agent Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Angiogenesis Therapeutic Agent Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Angiogenesis Therapeutic Agent Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Angiogenesis Therapeutic Agent Market by Type
  1. 4.1 Angiogenesis Therapeutic Agent Type Introduction
  2. 4.1.1 Diabetic Retinopathy
  3. 4.1.2 Myopic Choroidal Neovascularization
  4. 4.1.3 Macular Edema
  5. 4.1.4 Macular Degeneration
  6. 4.2 Global Angiogenesis Therapeutic Agent Sales Volume by Type
  7. 4.2.1 Global Angiogenesis Therapeutic Agent Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Angiogenesis Therapeutic Agent Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Angiogenesis Therapeutic Agent Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Angiogenesis Therapeutic Agent Sales Value by Type
  11. 4.3.1 Global Angiogenesis Therapeutic Agent Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Angiogenesis Therapeutic Agent Sales Value by Type (2021-2032)
  13. 4.3.3 Global Angiogenesis Therapeutic Agent Sales Value Share by Type (2021-2032)
5 Angiogenesis Therapeutic Agent Market by Application
  1. 5.1 Angiogenesis Therapeutic Agent Application Introduction
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Angiogenesis Therapeutic Agent Sales Volume by Application
  6. 5.2.1 Global Angiogenesis Therapeutic Agent Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Angiogenesis Therapeutic Agent Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Angiogenesis Therapeutic Agent Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Angiogenesis Therapeutic Agent Sales Value by Application
  10. 5.3.1 Global Angiogenesis Therapeutic Agent Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Angiogenesis Therapeutic Agent Sales Value by Application (2021-2032)
  12. 5.3.3 Global Angiogenesis Therapeutic Agent Sales Value Share by Application (2021-2032)
6 Angiogenesis Therapeutic Agent Regional Sales and Value Analysis
  1. 6.1 Global Angiogenesis Therapeutic Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiogenesis Therapeutic Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Angiogenesis Therapeutic Agent Sales by Region: 2021-2026
  4. 6.2.2 Global Angiogenesis Therapeutic Agent Sales by Region (2027-2032)
  5. 6.3 Global Angiogenesis Therapeutic Agent Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Angiogenesis Therapeutic Agent Sales Value by Region (2021-2032)
  7. 6.4.1 Global Angiogenesis Therapeutic Agent Sales Value by Region: 2021-2026
  8. 6.4.2 Global Angiogenesis Therapeutic Agent Sales Value by Region (2027-2032)
  9. 6.5 Global Angiogenesis Therapeutic Agent Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Angiogenesis Therapeutic Agent Sales Value (2021-2032)
  12. 6.6.2 North America Angiogenesis Therapeutic Agent Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Angiogenesis Therapeutic Agent Sales Value (2021-2032)
  15. 6.7.2 Europe Angiogenesis Therapeutic Agent Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Angiogenesis Therapeutic Agent Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Angiogenesis Therapeutic Agent Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Angiogenesis Therapeutic Agent Sales Value (2021-2032)
  21. 6.9.2 South America Angiogenesis Therapeutic Agent Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Angiogenesis Therapeutic Agent Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Angiogenesis Therapeutic Agent Sales Value Share by Country, 2025 VS 2032
7 Angiogenesis Therapeutic Agent Country-level Sales and Value Analysis
  1. 7.1 Global Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Angiogenesis Therapeutic Agent Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
  4. 7.3.1 Global Angiogenesis Therapeutic Agent Sales by Country (2021-2026)
  5. 7.3.2 Global Angiogenesis Therapeutic Agent Sales by Country (2027-2032)
  6. 7.4 Global Angiogenesis Therapeutic Agent Sales Value by Country (2021-2032)
  7. 7.4.1 Global Angiogenesis Therapeutic Agent Sales Value by Country (2021-2026)
  8. 7.4.2 Global Angiogenesis Therapeutic Agent Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Angiogenesis Therapeutic Agent Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Angiogenesis Therapeutic Agent Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Angiogenesis Therapeutic Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharma
  2. 8.1.1 Sun Pharma Company Information
  3. 8.1.2 Sun Pharma Business Overview
  4. 8.1.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio
  6. 8.1.5 Sun Pharma Recent Developments
  7. 8.2 Shanghai Pharmaceuticals
  8. 8.2.1 Shanghai Pharmaceuticals Company Information
  9. 8.2.2 Shanghai Pharmaceuticals Business Overview
  10. 8.2.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio
  12. 8.2.5 Shanghai Pharmaceuticals Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Angiogenesis Therapeutic Agent Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Gilead Sciences, Inc.
  26. 8.5.1 Gilead Sciences, Inc. Company Information
  27. 8.5.2 Gilead Sciences, Inc. Business Overview
  28. 8.5.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  30. 8.5.5 Gilead Sciences, Inc. Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Angiogenesis Therapeutic Agent Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Daiichi Sankyo
  38. 8.7.1 Daiichi Sankyo Company Information
  39. 8.7.2 Daiichi Sankyo Business Overview
  40. 8.7.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio
  42. 8.7.5 Daiichi Sankyo Recent Developments
  43. 8.8 Bayer AG
  44. 8.8.1 Bayer AG Company Information
  45. 8.8.2 Bayer AG Business Overview
  46. 8.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Portfolio
  48. 8.8.5 Bayer AG Recent Developments
  49. 8.9 The Geuder Group, MORCHER GmbH
  50. 8.9.1 The Geuder Group, MORCHER GmbH Company Information
  51. 8.9.2 The Geuder Group, MORCHER GmbH Business Overview
  52. 8.9.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio
  54. 8.9.5 The Geuder Group, MORCHER GmbH Recent Developments
  55. 8.10 Santen Pharmaceutical Co., Ltd.
  56. 8.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio
  60. 8.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Regeneron Pharmaceuticals, Inc.
  62. 8.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  66. 8.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 8.12 Otsuka Pharmaceutical Co. Ltd
  68. 8.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 8.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 8.12.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio
  72. 8.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 8.13 Novamedika
  74. 8.13.1 Novamedika Company Information
  75. 8.13.2 Novamedika Business Overview
  76. 8.13.3 Novamedika Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Novamedika Angiogenesis Therapeutic Agent Product Portfolio
  78. 8.13.5 Novamedika Recent Developments
  79. 8.14 Medicom Health care
  80. 8.14.1 Medicom Health care Company Information
  81. 8.14.2 Medicom Health care Business Overview
  82. 8.14.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio
  84. 8.14.5 Medicom Health care Recent Developments
  85. 8.15 Implandata ophthalmic products GmbH
  86. 8.15.1 Implandata ophthalmic products GmbH Company Information
  87. 8.15.2 Implandata ophthalmic products GmbH Business Overview
  88. 8.15.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio
  90. 8.15.5 Implandata ophthalmic products GmbH Recent Developments
  91. 8.16 Genentech, Inc.
  92. 8.16.1 Genentech, Inc. Company Information
  93. 8.16.2 Genentech, Inc. Business Overview
  94. 8.16.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  96. 8.16.5 Genentech, Inc. Recent Developments
  97. 8.17 Eyetech Inc.
  98. 8.17.1 Eyetech Inc. Company Information
  99. 8.17.2 Eyetech Inc. Business Overview
  100. 8.17.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio
  102. 8.17.5 Eyetech Inc. Recent Developments
  103. 8.18 ERC Labs
  104. 8.18.1 ERC Labs Company Information
  105. 8.18.2 ERC Labs Business Overview
  106. 8.18.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 ERC Labs Angiogenesis Therapeutic Agent Product Portfolio
  108. 8.18.5 ERC Labs Recent Developments
  109. 8.19 Becton, Dickinson and Company
  110. 8.19.1 Becton, Dickinson and Company Company Information
  111. 8.19.2 Becton, Dickinson and Company Business Overview
  112. 8.19.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio
  114. 8.19.5 Becton, Dickinson and Company Recent Developments
  115. 8.20 Allergan plc
  116. 8.20.1 Allergan plc Company Information
  117. 8.20.2 Allergan plc Business Overview
  118. 8.20.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Allergan plc Angiogenesis Therapeutic Agent Product Portfolio
  120. 8.20.5 Allergan plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiogenesis Therapeutic Agent Value Chain Analysis
  2. 9.1.1 Angiogenesis Therapeutic Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiogenesis Therapeutic Agent Sales Mode & Process
  6. 9.2 Angiogenesis Therapeutic Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiogenesis Therapeutic Agent Distributors
  9. 9.2.3 Angiogenesis Therapeutic Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst